Vascular endothelial growth factor and basic fibroblast growth factor in exudative age-related macular degeneration and diffuse diabetic macular edema

Ophthalmic Research

Volumn 39, Issue 3, 2007, Pages 139-142

  Jonas, Jost B ^a,b   Neumaier, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Basic fibroblast growth factor; Diabetic macular edema; Exudative age related macular degeneration; Vascular endothelial growth factor

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EVALUATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; SOLID PHASE SYNTHESIS;

EID: 34250887456     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102935     Document Type: Article

References (26)

1. Michaelson IC: The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948;68:137-180.
2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
4. Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina 2005;25:111-118.
5. Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal diseases. N Engl J Med 1994;331:1480-1487.
6. Aiello LP, Pierce EA, Foley ED, Takagi H, Dhen H, Riddle L, Ferrara N, King GL, Smith LE: Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-10461.
7. Tolentino MJ, Miller JW, Gragoudas ES, et al: Intravenous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828.
8. Tolentino MJ, Miller JW, Gragoudas ES, et al: Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996;114:964-970.
9. Adamis AP, Shima DT, Tolentino MJ, et al: Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66-71.
10. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT: Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154-162.
11. Kitaoka T, Morse LS, Schneeberger S, Ishigooka H, Hjelmeland LM: Expression of FGF5 in choroidal neovascular membranes associated with ARMD. Curr Eye Res 1997;16:396-399.
12. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M: Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-353.
13. Hera R, Keramidas M, Peoc'h M, et al: Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthal mol 2005;139:589-596.
14. Tong JP, Chan WM, Liu DT, Lay TY, Choy KW, Pang CP, Lam DS: Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141:456-462.
15. Funatsu H, Yamashita H, Nakamura S, et al: Vitreous levels of pigment epithelium derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006;113:294-301.
16. Jonas JB: Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006;38:218-245.
17. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant macular edema. Ophthalmology 2006;113:1706-1712.
18. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ, Wendel R, Patel A: Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-1705.
19. Jonas JB, Kreissig I, Degenring RF: Endophthalmitis after intravitreal injection of triamcinolone acetonide. Arch Ophthalmol 2003;121:1663-1664.
20. Noma H, Funatsu H, Yamasaki M, Tsukamoto H, Mimura T, Sone T, Hirayama T, Tamura H, Yamashita H, Minamoto A, Mishima HK: Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 2006, E-pub ahead of print.
21. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al: Pegabtanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
22. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-372.
23. Rosenfeld PJ, Fung AE, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-339.
24. Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
25. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383-390.
26. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzales S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G: Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.